Tags Archive Navigation
icon
-
StoryA scientist from the start – Q&A with NIBR President Fiona Marshall
-
StoryRenewing our commitment to neglected tropical disease and malaria elimination
-
Featured NewsNovartis at ASCO and EHA 2022
-
Media ReleaseNovartis and Molecular Partners report positive topline data from Phase 2 study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19
-
Media ReleaseNovartis provides an update on Phase III ligelizumab (QGE031) studies in chronic spontaneous urticaria (CSU)
-
Media ReleaseNovartis R&D day spotlights attractive growth profile, underpinned by strong in-market brands, 20 potential high value pipeline assets, and technology platforms
-
StoryThe art of drug design in a technological age
-
StoryTo make a difference, start with patients
-
Media ReleaseNovartis Provides Update on AVXS-101 Intrathecal Clinical Development Program
-
Media ReleaseNovartis received European Medicines Agency (EMA) PRIME designation for iptacopan (LNP) in C3 glomerulopathy (C3G)
-
Media ReleaseEn 2020, Novartis a enregistré une croissance de son chiffre d’affaires et de sa marge; il a continué de faire progresser sa prochaine vague de médicaments
-
Media ReleaseNovartis hat 2020 Umsatz und Margen gesteigert und die nächste Welle von Medikamenten weiter vorangetrieben
Pagination
- 1
- 2
- 3
- 4
- › Next page